SCHEDULE: FMR LLC Reports Stake in First Tracks Biotherapeutics

FMR LLC and Abigail P. Johnson have reported a beneficial ownership stake of 5.9% in First Tracks Biotherapeutics Inc. as of June 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson, through various subsidiaries and affiliates, collectively hold a beneficial ownership of 2,054,127.49 shares of First Tracks Biotherapeutics Inc. common stock.
• This holding represents 5.9% of the class of securities.
• The filing is made under Schedule 13G, indicating passive investment.
• The reporting persons have sole voting power and sole dispositive power over these shares.
• The date of the event requiring this filing is June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership percentage without new operational or financial disclosures.

Positives

• FMR LLC and Abigail P. Johnson maintain a significant passive investment stake, suggesting confidence in the company's long-term prospects.
• The reporting persons have sole voting and dispositive power, indicating clear control over their investment decisions.

Negatives

• The filing does not provide any new operational or financial performance data for First Tracks Biotherapeutics Inc.
• The increase or decrease in ownership percentage compared to previous filings is not detailed within this specific document, making it difficult to assess recent investment activity.

Risks

• As a Schedule 13G filing, it indicates a passive investment, meaning FMR LLC and Abigail P. Johnson are not actively seeking to control or influence the issuer.
• The filing does not contain forward-looking statements or specific business strategies, thus offering no insight into future company performance or potential risks.

Future Outlook

This filing is a Schedule 13G, which reports beneficial ownership and does not contain forward-looking statements or company guidance.

Management Comments

• FMR LLC and Abigail P. Johnson may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC.
• This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the 'FMR Reporters').

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by FMR LLC and Abigail P. Johnson indicates a significant passive investment in First Tracks Biotherapeutics Inc. Such filings are common for large institutional investors and signify a stake below the threshold that would trigger a Schedule 13D filing, which requires more detailed disclosures about investment intent.

Stakeholder Impact

• Shareholders: The filing confirms a significant passive investment by FMR LLC and Abigail P. Johnson, which can be viewed as a sign of institutional confidence, potentially stabilizing or positively influencing market perception.
• Management: The passive nature of the investment suggests no immediate intent to influence corporate control or strategy by the reporting persons.

Next Steps

• Continued monitoring of First Tracks Biotherapeutics Inc. for future operational and financial updates.
• Observation of any changes in FMR LLC's or Abigail P. Johnson's beneficial ownership percentage.

Key Dates

Keywords

First Tracks Biotherapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Investment, Common Stock